Business, energy, technology, markets and global industry news from Business News Today

Kyverna Therapeutics

PharmaDeviceNews Kyverna Therapeutics
Representative image: Kyverna Therapeutics’ miv-cel shows durable one-year mobility gains in stiff person syndrome as the CAR T therapy advances toward FDA review.
Pharma & Biotech

Miv-cel sustains one-year SPS benefit as Kyverna advances CAR T therapy toward FDA filing

Kyverna’s miv-cel sustains mobility gains and keeps 92% of SPS patients off chronic immunotherapy at one year as its FDA filing advances.

Read More
Fate Therapeutics has dosed the first participant in the Phase 2 RECLAIM-LN study of FT819, its off-the-shelf CD19-directed CAR T-cell therapy being evaluated for refractory moderate-to-severe lupus nephritis. Representative image.
Pharma & Biotech

Fate Therapeutics starts potentially registrational FT819 trial in lupus nephritis

Fate Therapeutics has treated the first participant in RECLAIM-LN, a Phase 2 study evaluating its off-the-shelf CD19-directed CAR T-cell candidate FT819 in people with refractory moderate-to-severe lupus nephritis. The company disclosed the trial initiation on August 14, 2026, saying the first participant received FT819 in an outpatient setting and was discharged on the same day.

Read More